JP2010530901A5 - - Google Patents

Info

Publication number

JP2010530901A5

JP2010530901A5 JP2010513485A JP2010513485A JP2010530901A5 JP 2010530901 A5 JP2010530901 A5 JP 2010530901A5 JP 2010513485 A JP2010513485 A JP 2010513485A JP 2010513485 A JP2010513485 A JP 2010513485A JP 2010530901 A5 JP2010530901 A5 JP 2010530901A5

Authority

JP

Japan

Prior art keywords

pain

trpa1

alkyl

compounds

substituted

Prior art date

2008-06-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 description 267
• 208000002193 Pain Diseases 0.000 description 241
• 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 225
• 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 225
• 230000036407 pain Effects 0.000 description 213
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 133
• 125000005843 halogen group Chemical group 0.000 description 133
• 239000003112 inhibitor Substances 0.000 description 123
• 125000000623 heterocyclic group Chemical group 0.000 description 117
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 114
• 125000001072 heteroaryl group Chemical group 0.000 description 103
• 125000003118 aryl group Chemical group 0.000 description 102
• 208000024891 symptom Diseases 0.000 description 99
• 150000001408 amides Chemical class 0.000 description 91
• 201000010099 disease Diseases 0.000 description 91
• 230000000694 effects Effects 0.000 description 91
• 125000000217 alkyl group Chemical group 0.000 description 86
• 238000011282 treatment Methods 0.000 description 85
• 238000000034 method Methods 0.000 description 77
• 230000006870 function Effects 0.000 description 74
• 230000006378 damage Effects 0.000 description 69
• 125000004122 cyclic group Chemical group 0.000 description 63
• -1 amino, amidyl Chemical group 0.000 description 62
• 230000001404 mediated effect Effects 0.000 description 59
• 125000003545 alkoxy group Chemical group 0.000 description 58
• 229910052757 nitrogen Inorganic materials 0.000 description 58
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 57
• 208000014674 injury Diseases 0.000 description 55
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 53
• 208000027418 Wounds and injury Diseases 0.000 description 52
• 210000000214 mouth Anatomy 0.000 description 51
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 51
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 50
• 125000002252 acyl group Chemical group 0.000 description 48
• 125000004093 cyano group Chemical group *C#N 0.000 description 46
• 125000004663 dialkyl amino group Chemical group 0.000 description 46
• 239000000203 mixture Substances 0.000 description 46
• 125000003282 alkyl amino group Chemical group 0.000 description 45
• 239000005557 antagonist Substances 0.000 description 45
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 43
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 43
• 208000035475 disorder Diseases 0.000 description 42
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 38
• 239000003814 drug Substances 0.000 description 37
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 37
• 229940100389 Sulfonylurea Drugs 0.000 description 36
• 125000004104 aryloxy group Chemical group 0.000 description 36
• 235000013877 carbamide Nutrition 0.000 description 36
• 125000005864 sulfonamidyl group Chemical group 0.000 description 36
• 206010031009 Oral pain Diseases 0.000 description 35
• 229910052739 hydrogen Inorganic materials 0.000 description 34
• 229940123524 TRPA1 antagonist Drugs 0.000 description 33
• 206010061218 Inflammation Diseases 0.000 description 31
• 230000004054 inflammatory process Effects 0.000 description 31
• 206010021639 Incontinence Diseases 0.000 description 30
• 108090000862 Ion Channels Proteins 0.000 description 30
• 102000004310 Ion Channels Human genes 0.000 description 30
• 229940079593 drug Drugs 0.000 description 30
• 239000004202 carbamide Substances 0.000 description 29
• 125000001424 substituent group Chemical group 0.000 description 29
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 29
• 229910052717 sulfur Inorganic materials 0.000 description 28
• 241001465754 Metazoa Species 0.000 description 27
• 150000002500 ions Chemical class 0.000 description 27
• 239000011575 calcium Substances 0.000 description 26
• 210000004027 cell Anatomy 0.000 description 26
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 25
• 229910052799 carbon Inorganic materials 0.000 description 25
• 239000008194 pharmaceutical composition Substances 0.000 description 25
• 239000003795 chemical substances by application Substances 0.000 description 24
• 230000004907 flux Effects 0.000 description 24
• 150000003839 salts Chemical class 0.000 description 24
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 23
• 206010028980 Neoplasm Diseases 0.000 description 23
• 125000003342 alkenyl group Chemical group 0.000 description 23
• 201000011510 cancer Diseases 0.000 description 23
• 125000005842 heteroatom Chemical group 0.000 description 23
• 230000005764 inhibitory process Effects 0.000 description 23
• 230000004913 activation Effects 0.000 description 22
• 125000003710 aryl alkyl group Chemical group 0.000 description 22
• 239000001257 hydrogen Substances 0.000 description 22
• 208000003265 stomatitis Diseases 0.000 description 22
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 21
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
• 206010011224 Cough Diseases 0.000 description 20
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 20
• 208000007117 Oral Ulcer Diseases 0.000 description 20
• 206010033645 Pancreatitis Diseases 0.000 description 20
• 208000025865 Ulcer Diseases 0.000 description 20
• 238000009472 formulation Methods 0.000 description 20
• 108090000765 processed proteins & peptides Proteins 0.000 description 20
• 231100000397 ulcer Toxicity 0.000 description 20
• 208000001640 Fibromyalgia Diseases 0.000 description 19
• 208000004296 neuralgia Diseases 0.000 description 19
• 208000021722 neuropathic pain Diseases 0.000 description 19
• 229910052760 oxygen Inorganic materials 0.000 description 19
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
• 125000000304 alkynyl group Chemical group 0.000 description 18
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 17
• 208000000094 Chronic Pain Diseases 0.000 description 17
• 229910052791 calcium Inorganic materials 0.000 description 17
• 208000015181 infectious disease Diseases 0.000 description 17
• 102000004196 processed proteins & peptides Human genes 0.000 description 17
• 150000003384 small molecules Chemical class 0.000 description 17
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 15
• 206010065390 Inflammatory pain Diseases 0.000 description 15
• 206010033649 Pancreatitis chronic Diseases 0.000 description 15
• 238000010171 animal model Methods 0.000 description 15
• 125000000753 cycloalkyl group Chemical group 0.000 description 15
• 150000002431 hydrogen Chemical class 0.000 description 15
• 125000003729 nucleotide group Chemical group 0.000 description 15
• 230000001354 painful effect Effects 0.000 description 15
• 229920001184 polypeptide Polymers 0.000 description 15
• 208000004454 Hyperalgesia Diseases 0.000 description 14
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
• 230000001965 increasing effect Effects 0.000 description 14
• 239000002773 nucleotide Substances 0.000 description 14
• 108091006146 Channels Proteins 0.000 description 13
• 201000004624 Dermatitis Diseases 0.000 description 13
• 241000700159 Rattus Species 0.000 description 13
• 230000001154 acute effect Effects 0.000 description 13
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 13
• 210000003491 skin Anatomy 0.000 description 13
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 12
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
• 102000003566 TRPV1 Human genes 0.000 description 12
• 102000003568 TRPV3 Human genes 0.000 description 12
• 101150016206 Trpv1 gene Proteins 0.000 description 12
• 101150043371 Trpv3 gene Proteins 0.000 description 12
• 239000002253 acid Substances 0.000 description 12
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 12
• 238000000338 in vitro Methods 0.000 description 12
• 210000000496 pancreas Anatomy 0.000 description 12
• 206010058019 Cancer Pain Diseases 0.000 description 11
• 208000005232 Glossitis Diseases 0.000 description 11
• 102000003610 TRPM8 Human genes 0.000 description 11
• 101150111302 Trpm8 gene Proteins 0.000 description 11
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 11
• 210000003414 extremity Anatomy 0.000 description 11
• 230000014509 gene expression Effects 0.000 description 11
• 239000007924 injection Substances 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• 238000004519 manufacturing process Methods 0.000 description 11
• 229940005483 opioid analgesics Drugs 0.000 description 11
• 208000033808 peripheral neuropathy Diseases 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 229940124530 sulfonamide Drugs 0.000 description 11
• 238000001356 surgical procedure Methods 0.000 description 11
• 210000000515 tooth Anatomy 0.000 description 11
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
• 208000035154 Hyperesthesia Diseases 0.000 description 10
• 206010020751 Hypersensitivity Diseases 0.000 description 10
• 208000019695 Migraine disease Diseases 0.000 description 10
• 125000004414 alkyl thio group Chemical group 0.000 description 10
• ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 10
• 125000003275 alpha amino acid group Chemical group 0.000 description 10
• 125000004429 atom Chemical group 0.000 description 10
• 239000002585 base Substances 0.000 description 10
• 230000006399 behavior Effects 0.000 description 10
• 125000005265 dialkylamine group Chemical group 0.000 description 10
• 210000002683 foot Anatomy 0.000 description 10
• 229910052736 halogen Inorganic materials 0.000 description 10
• 150000002367 halogens Chemical class 0.000 description 10
• 230000003902 lesion Effects 0.000 description 10
• 206010027599 migraine Diseases 0.000 description 10
• 125000002757 morpholinyl group Chemical group 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 150000003456 sulfonamides Chemical class 0.000 description 10
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
• 206010033647 Pancreatitis acute Diseases 0.000 description 9
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 9
• 201000003229 acute pancreatitis Diseases 0.000 description 9
• 125000004432 carbon atom Chemical group C* 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 9
• 125000001183 hydrocarbyl group Chemical group 0.000 description 9
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 230000002757 inflammatory effect Effects 0.000 description 9
• 230000003834 intracellular effect Effects 0.000 description 9
• 230000002438 mitochondrial effect Effects 0.000 description 9
• 125000002950 monocyclic group Chemical group 0.000 description 9
• 208000015122 neurodegenerative disease Diseases 0.000 description 9
• 206010039073 rheumatoid arthritis Diseases 0.000 description 9
• 238000006467 substitution reaction Methods 0.000 description 9
• 208000011580 syndromic disease Diseases 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 8
• 208000007514 Herpes zoster Diseases 0.000 description 8
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
• 108010036769 TRPA1 Cation Channel Proteins 0.000 description 8
• 102000012253 TRPA1 Cation Channel Human genes 0.000 description 8
• 150000001299 aldehydes Chemical class 0.000 description 8
• 230000003542 behavioural effect Effects 0.000 description 8
• 230000009460 calcium influx Effects 0.000 description 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
• 150000002148 esters Chemical class 0.000 description 8
• 210000000088 lip Anatomy 0.000 description 8
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
• 239000008164 mustard oil Substances 0.000 description 8
• 150000007523 nucleic acids Chemical class 0.000 description 8
• 108020004707 nucleic acids Proteins 0.000 description 8
• 102000039446 nucleic acids Human genes 0.000 description 8
• 239000001301 oxygen Substances 0.000 description 8
• 238000000554 physical therapy Methods 0.000 description 8
• 230000002265 prevention Effects 0.000 description 8
• 235000018102 proteins Nutrition 0.000 description 8
• 102000004169 proteins and genes Human genes 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 238000006722 reduction reaction Methods 0.000 description 8
• 230000035945 sensitivity Effects 0.000 description 8
• 230000008961 swelling Effects 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 8
• 208000024827 Alzheimer disease Diseases 0.000 description 7
• 206010007134 Candida infections Diseases 0.000 description 7
• 108010078791 Carrier Proteins Proteins 0.000 description 7
• 208000001294 Nociceptive Pain Diseases 0.000 description 7
• 206010037660 Pyrexia Diseases 0.000 description 7
• 102000003567 TRPV4 Human genes 0.000 description 7
• 101150098315 TRPV4 gene Proteins 0.000 description 7
• 208000005298 acute pain Diseases 0.000 description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
• 201000003984 candidiasis Diseases 0.000 description 7
• 235000010418 carrageenan Nutrition 0.000 description 7
• 239000000679 carrageenan Substances 0.000 description 7
• 229920001525 carrageenan Polymers 0.000 description 7
• 229940113118 carrageenan Drugs 0.000 description 7
• 125000001309 chloro group Chemical group Cl* 0.000 description 7
• 230000001079 digestive effect Effects 0.000 description 7
• 206010013781 dry mouth Diseases 0.000 description 7
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
• 230000036571 hydration Effects 0.000 description 7
• 238000006703 hydration reaction Methods 0.000 description 7
• 238000000099 in vitro assay Methods 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 208000002551 irritable bowel syndrome Diseases 0.000 description 7
• 230000033001 locomotion Effects 0.000 description 7
• 238000007726 management method Methods 0.000 description 7
• 210000003205 muscle Anatomy 0.000 description 7
• 210000005036 nerve Anatomy 0.000 description 7
• 230000003040 nociceptive effect Effects 0.000 description 7
• 235000016709 nutrition Nutrition 0.000 description 7
• 239000003921 oil Substances 0.000 description 7
• 235000019198 oils Nutrition 0.000 description 7
• 125000004043 oxo group Chemical group O=* 0.000 description 7
• 230000002085 persistent effect Effects 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 229940002612 prodrug Drugs 0.000 description 7
• 239000000651 prodrug Substances 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• 239000011593 sulfur Substances 0.000 description 7
• 150000003672 ureas Chemical class 0.000 description 7
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 7
• 206010005949 Bone cancer Diseases 0.000 description 6
• 208000018084 Bone neoplasm Diseases 0.000 description 6
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
• 241000222122 Candida albicans Species 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
• 206010061291 Mineral deficiency Diseases 0.000 description 6
• 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 6
• 201000004681 Psoriasis Diseases 0.000 description 6
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 6
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
• 102000003570 TRPV5 Human genes 0.000 description 6
• 102000003569 TRPV6 Human genes 0.000 description 6
• 101150096736 TRPV6 gene Proteins 0.000 description 6
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
• 101150034091 Trpv5 gene Proteins 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 208000010668 atopic eczema Diseases 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 238000002512 chemotherapy Methods 0.000 description 6
• CISNNLXXANUBPI-UHFFFAOYSA-N cyano(nitro)azanide Chemical compound [O-][N+](=O)[N-]C#N CISNNLXXANUBPI-UHFFFAOYSA-N 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 238000009396 hybridization Methods 0.000 description 6
• 208000027866 inflammatory disease Diseases 0.000 description 6
• 210000001847 jaw Anatomy 0.000 description 6
• 150000002576 ketones Chemical class 0.000 description 6
• 239000002207 metabolite Substances 0.000 description 6
• 230000035764 nutrition Effects 0.000 description 6
• 201000008482 osteoarthritis Diseases 0.000 description 6
• 230000001590 oxidative effect Effects 0.000 description 6
• ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 6
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 6
• 210000003296 saliva Anatomy 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• 210000000278 spinal cord Anatomy 0.000 description 6
• 230000035882 stress Effects 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 239000000606 toothpaste Substances 0.000 description 6
• 230000008733 trauma Effects 0.000 description 6
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
• 102000003678 AMPA Receptors Human genes 0.000 description 5
• 108090000078 AMPA Receptors Proteins 0.000 description 5
• 208000000412 Avitaminosis Diseases 0.000 description 5
• 206010004146 Basal cell carcinoma Diseases 0.000 description 5
• 108091005462 Cation channels Proteins 0.000 description 5
• 241000700198 Cavia Species 0.000 description 5
• 208000018522 Gastrointestinal disease Diseases 0.000 description 5
• 206010019233 Headaches Diseases 0.000 description 5
• 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 5
• 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 5
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 5
• 229910019142 PO4 Inorganic materials 0.000 description 5
• 208000004550 Postoperative Pain Diseases 0.000 description 5
• 208000003251 Pruritus Diseases 0.000 description 5
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
• 208000036142 Viral infection Diseases 0.000 description 5
• 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 5
• 102100033024 Voltage-dependent T-type calcium channel subunit alpha-1G Human genes 0.000 description 5
• 208000026935 allergic disease Diseases 0.000 description 5
• 230000007815 allergy Effects 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
• 229940035676 analgesics Drugs 0.000 description 5
• 239000000730 antalgic agent Substances 0.000 description 5
• 230000003110 anti-inflammatory effect Effects 0.000 description 5
• 230000033228 biological regulation Effects 0.000 description 5
• 230000005540 biological transmission Effects 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 125000000392 cycloalkenyl group Chemical group 0.000 description 5
• 201000003146 cystitis Diseases 0.000 description 5
• 208000002925 dental caries Diseases 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 238000002651 drug therapy Methods 0.000 description 5
• 201000006549 dyspepsia Diseases 0.000 description 5
• 235000013305 food Nutrition 0.000 description 5
• 125000000524 functional group Chemical group 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 239000002324 mouth wash Substances 0.000 description 5
• 230000004770 neurodegeneration Effects 0.000 description 5
• 201000001119 neuropathy Diseases 0.000 description 5
• 230000007823 neuropathy Effects 0.000 description 5
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
• 208000035824 paresthesia Diseases 0.000 description 5
• 210000000578 peripheral nerve Anatomy 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 239000010452 phosphate Chemical group 0.000 description 5
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
• 108091033319 polynucleotide Proteins 0.000 description 5
• 102000040430 polynucleotide Human genes 0.000 description 5
• 239000002157 polynucleotide Substances 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000035807 sensation Effects 0.000 description 5
• 235000019615 sensations Nutrition 0.000 description 5
• 208000017520 skin disease Diseases 0.000 description 5
• 229910052708 sodium Inorganic materials 0.000 description 5
• 239000012453 solvate Substances 0.000 description 5
• 206010041823 squamous cell carcinoma Diseases 0.000 description 5
• 125000000547 substituted alkyl group Chemical group 0.000 description 5
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
• 150000007970 thio esters Chemical class 0.000 description 5
• 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 5
• 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 5
• 238000012384 transportation and delivery Methods 0.000 description 5
• 230000009385 viral infection Effects 0.000 description 5
• 208000009935 visceral pain Diseases 0.000 description 5
• 229940088594 vitamin Drugs 0.000 description 5
• 229930003231 vitamin Natural products 0.000 description 5
• 235000013343 vitamin Nutrition 0.000 description 5
• 239000011782 vitamin Substances 0.000 description 5
• 206010001497 Agitation Diseases 0.000 description 4
• 101800004538 Bradykinin Proteins 0.000 description 4
• 102400000967 Bradykinin Human genes 0.000 description 4
• 102000003922 Calcium Channels Human genes 0.000 description 4
• 108090000312 Calcium Channels Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 4
• 101000729474 Homo sapiens DNA-directed RNA polymerase I subunit RPA1 Proteins 0.000 description 4
• 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• 206010020853 Hypertonic bladder Diseases 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
• 208000009722 Overactive Urinary Bladder Diseases 0.000 description 4
• 206010033799 Paralysis Diseases 0.000 description 4
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
• 102100035729 Replication protein A 70 kDa DNA-binding subunit Human genes 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 102000003565 TRPV2 Human genes 0.000 description 4
• 206010044016 Tooth abscess Diseases 0.000 description 4
• 101150077905 Trpv2 gene Proteins 0.000 description 4
• 206010047627 Vitamin deficiencies Diseases 0.000 description 4
• 206010047700 Vomiting Diseases 0.000 description 4
• 206010000269 abscess Diseases 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 229940024606 amino acid Drugs 0.000 description 4
• 150000001413 amino acids Chemical class 0.000 description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• 230000003444 anaesthetic effect Effects 0.000 description 4
• 230000036592 analgesia Effects 0.000 description 4
• 230000000202 analgesic effect Effects 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 239000003443 antiviral agent Substances 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 4
• 230000004094 calcium homeostasis Effects 0.000 description 4
• 230000003185 calcium uptake Effects 0.000 description 4
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
• 208000037765 diseases and disorders Diseases 0.000 description 4
• 210000003238 esophagus Anatomy 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 206010016256 fatigue Diseases 0.000 description 4
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 230000003779 hair growth Effects 0.000 description 4
• 231100000869 headache Toxicity 0.000 description 4
• 208000024798 heartburn Diseases 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 230000010291 membrane polarization Effects 0.000 description 4
• SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 4
• 229960005181 morphine Drugs 0.000 description 4
• 230000000926 neurological effect Effects 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
• 150000002894 organic compounds Chemical class 0.000 description 4
• 208000020629 overactive bladder Diseases 0.000 description 4
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 4
• 125000003367 polycyclic group Polymers 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 4
• 210000004872 soft tissue Anatomy 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 208000020431 spinal cord injury Diseases 0.000 description 4
• 210000001032 spinal nerve Anatomy 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000011285 therapeutic regimen Methods 0.000 description 4
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
• 229940034610 toothpaste Drugs 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 150000003722 vitamin derivatives Chemical class 0.000 description 4
• 230000008673 vomiting Effects 0.000 description 4
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 206010006784 Burning sensation Diseases 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 208000024720 Fabry Disease Diseases 0.000 description 3
• 206010017533 Fungal infection Diseases 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 208000002720 Malnutrition Diseases 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 102000004129 N-Type Calcium Channels Human genes 0.000 description 3
• 108090000699 N-Type Calcium Channels Proteins 0.000 description 3
• 206010028813 Nausea Diseases 0.000 description 3
• 208000028389 Nerve injury Diseases 0.000 description 3
• 208000007920 Neurogenic Inflammation Diseases 0.000 description 3
• 239000008896 Opium Substances 0.000 description 3
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
• 206010033372 Pain and discomfort Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 102000011213 Transient receptor potential channel, canonical 6 Human genes 0.000 description 3
• 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 3
• 206010064390 Tumour invasion Diseases 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 206010052428 Wound Diseases 0.000 description 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000036982 action potential Effects 0.000 description 3
• 125000004423 acyloxy group Chemical group 0.000 description 3
• 125000004171 alkoxy aryl group Chemical group 0.000 description 3
• 239000013566 allergen Substances 0.000 description 3
• 229940035674 anesthetics Drugs 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 229940121375 antifungal agent Drugs 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000009400 cancer invasion Effects 0.000 description 3
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 229940044683 chemotherapy drug Drugs 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 125000004966 cyanoalkyl group Chemical group 0.000 description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000018044 dehydration Effects 0.000 description 3
• 238000006297 dehydration reaction Methods 0.000 description 3
• 201000003515 dental abscess Diseases 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 230000035622 drinking Effects 0.000 description 3
• 125000006575 electron-withdrawing group Chemical group 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• 235000019441 ethanol Nutrition 0.000 description 3
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 239000003193 general anesthetic agent Substances 0.000 description 3
• 125000001188 haloalkyl group Chemical group 0.000 description 3
• 208000014829 head and neck neoplasm Diseases 0.000 description 3
• 230000013632 homeostatic process Effects 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 150000002430 hydrocarbons Chemical class 0.000 description 3
• 150000003949 imides Chemical class 0.000 description 3
• 150000002466 imines Chemical group 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000007913 intrathecal administration Methods 0.000 description 3
• 239000002085 irritant Substances 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000000111 lower esophageal sphincter Anatomy 0.000 description 3
• 230000001071 malnutrition Effects 0.000 description 3
• 235000000824 malnutrition Nutrition 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000028161 membrane depolarization Effects 0.000 description 3
• 208000030159 metabolic disease Diseases 0.000 description 3
• AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 3
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
• 229940051866 mouthwash Drugs 0.000 description 3
• 210000004400 mucous membrane Anatomy 0.000 description 3
• DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 3
• 230000008693 nausea Effects 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 208000015380 nutritional deficiency disease Diseases 0.000 description 3
• 229960001027 opium Drugs 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• 230000004962 physiological condition Effects 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 150000003180 prostaglandins Chemical class 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
• 230000001698 pyrogenic effect Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 210000004927 skin cell Anatomy 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 150000003462 sulfoxides Chemical class 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 230000003685 thermal hair damage Effects 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 229930192474 thiophene Chemical group 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 3
• 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
• QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
• UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
• QITVRBREBFELAB-HCWSKCQFSA-N 1-[(2R,3R,4S,5R)-2-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(N=[N+]=[N-])N1C(=O)NC(=O)C=C1 QITVRBREBFELAB-HCWSKCQFSA-N 0.000 description 2
• PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• 206010000087 Abdominal pain upper Diseases 0.000 description 2
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
• 208000007848 Alcoholism Diseases 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• 208000006820 Arthralgia Diseases 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 229930003347 Atropine Natural products 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• 102000017927 CHRM1 Human genes 0.000 description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 description 2
• 101150073075 Chrm1 gene Proteins 0.000 description 2
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
• 206010016059 Facial pain Diseases 0.000 description 2
• 240000008620 Fagopyrum esculentum Species 0.000 description 2
• 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• 208000037357 HIV infectious disease Diseases 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 208000033830 Hot Flashes Diseases 0.000 description 2
• 206010060800 Hot flush Diseases 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 208000029462 Immunodeficiency disease Diseases 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
• 229930064664 L-arginine Natural products 0.000 description 2
• 235000014852 L-arginine Nutrition 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 208000001388 Opportunistic Infections Diseases 0.000 description 2
• 208000007027 Oral Candidiasis Diseases 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 206010033425 Pain in extremity Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• 241000721454 Pemphigus Species 0.000 description 2
• 208000010886 Peripheral nerve injury Diseases 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 208000005392 Spasm Diseases 0.000 description 2
• 102400000096 Substance P Human genes 0.000 description 2
• 101800003906 Substance P Proteins 0.000 description 2
• 229940123537 TRPM8 antagonist Drugs 0.000 description 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 108091006293 Uniporters Proteins 0.000 description 2
• 102000037089 Uniporters Human genes 0.000 description 2
• 206010046543 Urinary incontinence Diseases 0.000 description 2
• 206010047623 Vitamin C deficiency Diseases 0.000 description 2
• 208000005946 Xerostomia Diseases 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 125000002015 acyclic group Chemical group 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 201000007930 alcohol dependence Diseases 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 206010053552 allodynia Diseases 0.000 description 2
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
• 229960003805 amantadine Drugs 0.000 description 2
• 150000001409 amidines Chemical group 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 230000000954 anitussive effect Effects 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000003255 anti-acne Effects 0.000 description 2
• 230000000843 anti-fungal effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 230000001028 anti-proliverative effect Effects 0.000 description 2
• 230000002682 anti-psoriatic effect Effects 0.000 description 2
• 230000002421 anti-septic effect Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 239000000935 antidepressant agent Substances 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 229940124584 antitussives Drugs 0.000 description 2
• 230000036506 anxiety Effects 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
• 229960000396 atropine Drugs 0.000 description 2
• 150000001540 azides Chemical class 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000036765 blood level Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000000480 calcium channel blocker Substances 0.000 description 2
• 229910001424 calcium ion Inorganic materials 0.000 description 2
• 229960002504 capsaicin Drugs 0.000 description 2
• 235000017663 capsaicin Nutrition 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 125000004452 carbocyclyl group Chemical group 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000010001 cellular homeostasis Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• RJGHQTVXGKYATR-UHFFFAOYSA-L dibutyl(dichloro)stannane Chemical compound CCCC[Sn](Cl)(Cl)CCCC RJGHQTVXGKYATR-UHFFFAOYSA-L 0.000 description 2
• 229960001259 diclofenac Drugs 0.000 description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
• 229960002656 didanosine Drugs 0.000 description 2
• 102000038379 digestive enzymes Human genes 0.000 description 2
• 108091007734 digestive enzymes Proteins 0.000 description 2
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
• 229960005293 etodolac Drugs 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000004299 exfoliation Methods 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 2
• 229960001419 fenoprofen Drugs 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
• 239000011724 folic acid Substances 0.000 description 2
• 229960000304 folic acid Drugs 0.000 description 2
• 235000019152 folic acid Nutrition 0.000 description 2
• 210000004211 gastric acid Anatomy 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000003966 growth inhibitor Substances 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 210000002768 hair cell Anatomy 0.000 description 2
• 208000024963 hair loss Diseases 0.000 description 2
• 230000003676 hair loss Effects 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 125000004475 heteroaralkyl group Chemical group 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• 230000002102 hyperpolarization Effects 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 230000007813 immunodeficiency Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 229960000905 indomethacin Drugs 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 230000008991 intestinal motility Effects 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 231100000021 irritant Toxicity 0.000 description 2
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 239000003410 keratolytic agent Substances 0.000 description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
• 229960000991 ketoprofen Drugs 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 150000003951 lactams Chemical class 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 239000012669 liquid formulation Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 208000019423 liver disease Diseases 0.000 description 2
• 239000003589 local anesthetic agent Substances 0.000 description 2
• 229960005015 local anesthetics Drugs 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 229960003464 mefenamic acid Drugs 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• HHVOOJDLCVOLKI-VWLOTQADSA-N methyl (2S)-2-(dibenzylamino)-3-(1H-indol-3-yl)propanoate Chemical compound C=1C=CC=CC=1CN([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)OC)CC1=CC=CC=C1 HHVOOJDLCVOLKI-VWLOTQADSA-N 0.000 description 2
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
• 210000002200 mouth mucosa Anatomy 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000003551 muscarinic effect Effects 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
• 230000003533 narcotic effect Effects 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 239000002581 neurotoxin Substances 0.000 description 2
• 231100000618 neurotoxin Toxicity 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
• 125000006574 non-aromatic ring group Chemical group 0.000 description 2
• 125000005151 nonafluorobutanesulfonyl group Chemical group FC(C(C(S(=O)(=O)*)(F)F)(F)F)(C(F)(F)F)F 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 229940041672 oral gel Drugs 0.000 description 2
• 229940100692 oral suspension Drugs 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
• 229960002739 oxaprozin Drugs 0.000 description 2
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 230000008058 pain sensation Effects 0.000 description 2
• 210000000277 pancreatic duct Anatomy 0.000 description 2
• 125000001151 peptidyl group Chemical group 0.000 description 2
• RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
• 229960002702 piroxicam Drugs 0.000 description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 208000037920 primary disease Diseases 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 235000019260 propionic acid Nutrition 0.000 description 2
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
• 238000011552 rat model Methods 0.000 description 2
• 230000012481 regulation of membrane potential Effects 0.000 description 2
• 230000002040 relaxant effect Effects 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 238000007363 ring formation reaction Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 210000003497 sciatic nerve Anatomy 0.000 description 2
• 208000010233 scurvy Diseases 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• 230000036306 sensory inhibition Effects 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 210000003594 spinal ganglia Anatomy 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
• 229960000894 sulindac Drugs 0.000 description 2
• 230000035900 sweating Effects 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• FIGVVZUWCLSUEI-UHFFFAOYSA-N tricosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCC FIGVVZUWCLSUEI-UHFFFAOYSA-N 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
• 210000003708 urethra Anatomy 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
• UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
• UYTIHJQDXWDNQO-VAOFZXAKSA-N 1-[(2S,4S,5R)-2-(2-chloroethenyl)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(C=CCl)N1C(=O)NC(=O)C=C1 UYTIHJQDXWDNQO-VAOFZXAKSA-N 0.000 description 1
• MKXBOPXRKXGSTI-PJKMHFRUSA-N 1-[(2s,4s,5r)-2-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(F)O[C@H](CO)[C@@H](O)C1 MKXBOPXRKXGSTI-PJKMHFRUSA-N 0.000 description 1
• HBOMLICNUCNMMY-UHFFFAOYSA-N 1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(N=[N+]=[N-])C1 HBOMLICNUCNMMY-UHFFFAOYSA-N 0.000 description 1
• WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
• TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
• OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 description 1
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
• GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 description 1
• PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
• 240000002234 Allium sativum Species 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 229930183010 Amphotericin Natural products 0.000 description 1
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 244000099147 Ananas comosus Species 0.000 description 1
• 235000007119 Ananas comosus Nutrition 0.000 description 1
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• BWNWKKNJDBZGSM-RRKCRQDMSA-N BrC(C=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C=1)=O)=O)(Br)Br Chemical compound BrC(C=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C=1)=O)=O)(Br)Br BWNWKKNJDBZGSM-RRKCRQDMSA-N 0.000 description 1
• 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 206010006298 Breast pain Diseases 0.000 description 1
• 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
• 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• 108010009685 Cholinergic Receptors Proteins 0.000 description 1
• VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
• 235000005979 Citrus limon Nutrition 0.000 description 1
• 244000131522 Citrus pyriformis Species 0.000 description 1
• BHIHHJWSQVIVOR-RRKCRQDMSA-N ClC(C=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C=1)=O)=O)(Cl)Cl Chemical compound ClC(C=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C=1)=O)=O)(Cl)Cl BHIHHJWSQVIVOR-RRKCRQDMSA-N 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 208000003322 Coinfection Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 241000238424 Crustacea Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• 208000005156 Dehydration Diseases 0.000 description 1
• 208000018035 Dental disease Diseases 0.000 description 1
• LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 108700021097 Drosophila TrpA1 Proteins 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 206010013786 Dry skin Diseases 0.000 description 1
• 206010013935 Dysmenorrhoea Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 206010063601 Exposure to extreme temperature Diseases 0.000 description 1
• 206010015958 Eye pain Diseases 0.000 description 1
• 206010016326 Feeling cold Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 241000628997 Flos Species 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 240000009088 Fragaria x ananassa Species 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
• 206010018296 Gingivitis ulcerative Diseases 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
• 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 201000006219 Herpangina Diseases 0.000 description 1
• 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 240000005979 Hordeum vulgare Species 0.000 description 1
• 235000007340 Hordeum vulgare Nutrition 0.000 description 1
• YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical class [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
• 206010020601 Hyperchlorhydria Diseases 0.000 description 1
• 208000004044 Hypesthesia Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 206010021135 Hypovitaminosis Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
• 229940124091 Keratolytic Drugs 0.000 description 1
• 208000000913 Kidney Calculi Diseases 0.000 description 1
• GFXYTQPNNXGICT-YFKPBYRVSA-N L-allysine Chemical compound OC(=O)[C@@H](N)CCCC=O GFXYTQPNNXGICT-YFKPBYRVSA-N 0.000 description 1
• JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
• 206010024572 Lip ulceration Diseases 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 244000070406 Malus silvestris Species 0.000 description 1
• 208000006662 Mastodynia Diseases 0.000 description 1
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
• BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
• 206010061296 Motor dysfunction Diseases 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000029578 Muscle disease Diseases 0.000 description 1
• 206010049565 Muscle fatigue Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
• 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 206010029174 Nerve compression Diseases 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 101710138657 Neurotoxin Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 206010030973 Oral discomfort Diseases 0.000 description 1
• 206010048685 Oral infection Diseases 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
• 101150089079 PS1 gene Proteins 0.000 description 1
• 101150023107 PS2 gene Proteins 0.000 description 1
• 206010033627 Pancreatic injury Diseases 0.000 description 1
• 208000000450 Pelvic Pain Diseases 0.000 description 1
• JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010036618 Premenstrual syndrome Diseases 0.000 description 1
• 108010050254 Presenilins Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 206010051482 Prostatomegaly Diseases 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 241001098666 Pterois volitans Species 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 241000476150 Rat parvovirus 2 Species 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 206010038678 Respiratory depression Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• WBTCZXYOKNRFQX-UHFFFAOYSA-N S1(=O)(=O)NC1=O Chemical class S1(=O)(=O)NC1=O WBTCZXYOKNRFQX-UHFFFAOYSA-N 0.000 description 1
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
• 206010039424 Salivary hypersecretion Diseases 0.000 description 1
• 241000209056 Secale Species 0.000 description 1
• 235000007238 Secale cereale Nutrition 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 206010040021 Sensory abnormalities Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 206010040880 Skin irritation Diseases 0.000 description 1
• 206010040954 Skin wrinkling Diseases 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 240000003768 Solanum lycopersicum Species 0.000 description 1
• 208000029033 Spinal Cord disease Diseases 0.000 description 1
• 208000010040 Sprains and Strains Diseases 0.000 description 1
• XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• 208000010265 Sweet syndrome Diseases 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 229940126495 T-type calcium channel blocker Drugs 0.000 description 1
• 108060008646 TRPA Proteins 0.000 description 1
• 102000027545 TRPM Human genes 0.000 description 1
• 108091008847 TRPM Proteins 0.000 description 1
• 102000003563 TRPV Human genes 0.000 description 1
• 108060008564 TRPV Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010057040 Temperature intolerance Diseases 0.000 description 1
• 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
• 206010043269 Tension headache Diseases 0.000 description 1
• 208000008548 Tension-Type Headache Diseases 0.000 description 1
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
• 244000299461 Theobroma cacao Species 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 102100039175 Trefoil factor 1 Human genes 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 206010045171 Tumour pain Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 206010046809 Uterine pain Diseases 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 206010047095 Vascular pain Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 150000001241 acetals Chemical class 0.000 description 1
• 102000034337 acetylcholine receptors Human genes 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
• 239000000808 adrenergic beta-agonist Substances 0.000 description 1
• 238000012382 advanced drug delivery Methods 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000004479 aerosol dispenser Substances 0.000 description 1
• 210000003766 afferent neuron Anatomy 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 230000002009 allergenic effect Effects 0.000 description 1
• 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
• 229940061720 alpha hydroxy acid Drugs 0.000 description 1
• 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000005021 aminoalkenyl group Chemical group 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 125000005014 aminoalkynyl group Chemical group 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229940009444 amphotericin Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 229940069428 antacid Drugs 0.000 description 1
• 239000003159 antacid agent Substances 0.000 description 1
• 230000001458 anti-acid effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 230000003556 anti-epileptic effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000002460 anti-migrenic effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000002488 antieczema agent Substances 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
• 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
• 229940124433 antimigraine drug Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 229940064004 antiseptic throat preparations Drugs 0.000 description 1
• 229940121357 antivirals Drugs 0.000 description 1
• 208000002399 aphthous stomatitis Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 235000021016 apples Nutrition 0.000 description 1
• 210000000617 arm Anatomy 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 230000002938 autocide Effects 0.000 description 1
• 229960001671 azapropazone Drugs 0.000 description 1
• WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
• MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
• ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 208000003373 basosquamous carcinoma Diseases 0.000 description 1
• 230000003796 beauty Effects 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 238000003339 best practice Methods 0.000 description 1
• 150000001277 beta hydroxy acids Chemical class 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 229960001169 brivudine Drugs 0.000 description 1
• 210000005178 buccal mucosa Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
• 229960001113 butorphanol Drugs 0.000 description 1
• 230000028956 calcium-mediated signaling Effects 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 208000020670 canker sore Diseases 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000009084 cardiovascular function Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 239000004464 cereal grain Substances 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• WUTYZMFRCNBCHQ-PSASIEDQSA-N cevimeline Chemical compound C1S[C@H](C)O[C@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-PSASIEDQSA-N 0.000 description 1
• 229960001314 cevimeline Drugs 0.000 description 1
• 235000013351 cheese Nutrition 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 229910052729 chemical element Inorganic materials 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000002820 chemotaxin Substances 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 235000019219 chocolate Nutrition 0.000 description 1
• QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
• 208000023819 chronic asthma Diseases 0.000 description 1
• 208000013116 chronic cough Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 229960000724 cidofovir Drugs 0.000 description 1
• 235000017803 cinnamon Nutrition 0.000 description 1
• WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000035601 cold sensitivity Effects 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 230000009989 contractile response Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229940127071 cytotoxic antineoplastic agent Drugs 0.000 description 1
• 235000013365 dairy product Nutrition 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000008260 defense mechanism Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 229960003461 dezocine Drugs 0.000 description 1
• VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
• 238000013118 diabetic mouse model Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000020805 dietary restrictions Nutrition 0.000 description 1
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 230000037336 dry skin Effects 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 210000003027 ear inner Anatomy 0.000 description 1
• 230000008451 emotion Effects 0.000 description 1
• 230000006397 emotional response Effects 0.000 description 1
• 230000002121 endocytic effect Effects 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000036566 epidermal hyperplasia Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
• 229960002767 ethosuximide Drugs 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 230000003090 exacerbative effect Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000003172 expectorant agent Substances 0.000 description 1
• 230000003419 expectorant effect Effects 0.000 description 1
• 229940066493 expectorants Drugs 0.000 description 1
• 230000021824 exploration behavior Effects 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 239000003885 eye ointment Substances 0.000 description 1
• 229950003564 fiacitabine Drugs 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• 238000007716 flux method Methods 0.000 description 1
• 239000013568 food allergen Substances 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 210000004744 fore-foot Anatomy 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 235000012055 fruits and vegetables Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 150000002244 furazanes Chemical class 0.000 description 1
• 229960002870 gabapentin Drugs 0.000 description 1
• 208000001130 gallstones Diseases 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 210000000609 ganglia Anatomy 0.000 description 1
• 235000004611 garlic Nutrition 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001156 gastric mucosa Anatomy 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 210000004195 gingiva Anatomy 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 230000035929 gnawing Effects 0.000 description 1
• 230000003370 grooming effect Effects 0.000 description 1
• 238000009499 grossing Methods 0.000 description 1
• 229940124563 hair growth stimulant Drugs 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000008543 heat sensitivity Effects 0.000 description 1
• ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 1
• 150000002390 heteroarenes Chemical class 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 230000001632 homeopathic effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 235000021268 hot food Nutrition 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 229940071870 hydroiodic acid Drugs 0.000 description 1
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
• 229960001410 hydromorphone Drugs 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
• 229940005608 hypericin Drugs 0.000 description 1
• PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
• 208000034783 hypoesthesia Diseases 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 208000018879 impaired coordination Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000010262 intracellular communication Effects 0.000 description 1
• 210000005061 intracellular organelle Anatomy 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000000622 irritating effect Effects 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 210000000281 joint capsule Anatomy 0.000 description 1
• 230000001530 keratinolytic effect Effects 0.000 description 1
• 150000004715 keto acids Chemical class 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
• 229960003406 levorphanol Drugs 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 235000015263 low fat diet Nutrition 0.000 description 1
• 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 229960003803 meclofenamic acid Drugs 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960002509 miconazole Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 239000003149 muscarinic antagonist Substances 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
• JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 230000036562 nail growth Effects 0.000 description 1
• 229960000805 nalbuphine Drugs 0.000 description 1
• NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000008035 nerve activity Effects 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
• 230000008555 neuronal activation Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 229960000689 nevirapine Drugs 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 210000000929 nociceptor Anatomy 0.000 description 1
• 108091008700 nociceptors Proteins 0.000 description 1
• 125000005636 nonafluorobutanesulfonate group Chemical group 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000014571 nuts Nutrition 0.000 description 1
• 229960000988 nystatin Drugs 0.000 description 1
• VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 235000019645 odor Nutrition 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 230000027758 ovulation cycle Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229960005118 oxymorphone Drugs 0.000 description 1
• 229940124641 pain reliever Drugs 0.000 description 1
• 208000005877 painful neuropathy Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• 229960005301 pentazocine Drugs 0.000 description 1
• VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 229950000688 phenothiazine Drugs 0.000 description 1
• GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 229960001416 pilocarpine Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000036515 potency Effects 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• 206010036596 premature ejaculation Diseases 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 229940095574 propionic acid Drugs 0.000 description 1
• 150000005599 propionic acid derivatives Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
• 230000001107 psychogenic effect Effects 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 150000004040 pyrrolidinones Chemical class 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 210000003660 reticulum Anatomy 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 229960000329 ribavirin Drugs 0.000 description 1
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 229960000888 rimantadine Drugs 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• 229940063635 salagen Drugs 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 208000026451 salivation Diseases 0.000 description 1
• 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
• 229960002530 sargramostim Drugs 0.000 description 1
• 108010038379 sargramostim Proteins 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• 235000008790 seltzer Nutrition 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 230000012232 skeletal muscle contraction Effects 0.000 description 1
• 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
• 230000036556 skin irritation Effects 0.000 description 1
• 231100000475 skin irritation Toxicity 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 210000001584 soft palate Anatomy 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000024188 startle response Effects 0.000 description 1
• 229960001203 stavudine Drugs 0.000 description 1
• 208000001162 steatorrhea Diseases 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 235000021012 strawberries Nutrition 0.000 description 1
• 210000002330 subarachnoid space Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000008053 sultones Chemical class 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 229960005314 suramin Drugs 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 238000011521 systemic chemotherapy Methods 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 230000028016 temperature homeostasis Effects 0.000 description 1
• 208000001189 temporomandibular joint dysfunction syndrome Diseases 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
• GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
• 125000000101 thioether group Chemical group 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 208000002419 toxicodendron dermatitis Diseases 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 210000000427 trigeminal ganglion Anatomy 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 108091008848 trpn1 Proteins 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 208000030401 vitamin deficiency disease Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 230000037303 wrinkles Effects 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1